BRCA Mutations Associated With Carboplatin Outcomes in Triple-negative Breast Cancer

In subgroup analyses of BRCA mutation-status and average PFS, survival was longer in patients with BRCA mutations who were treated with carboplatin than BRCA-wildtype patients or BRCA-mutant status patients treated with docetaxel.

Reference

1. Tutt A, Cheang MCU, Kilburn L, et al. BRCA1 methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Paper presented at: 39^th San Antonio Breast Cancer Symposium; Dec 2016; San Antonio, TX.